化学療法による血栓縮小の理解:胃腸がん治療への影響

Supriya Peshin¹, Adit Dharia², Ehab Takrori³

¹Norton Community Hospital, Norton, VA 24273, USA.

Current oncology (Toronto, Ont.)

|August 27, 2025

まとめ

化学療法による血小板減少 (CIT) は,胃腸がんの頻繁な合併症であり,しばしば治療の遅延と出血を引き起こします. この見直しには,CITの詳細が記載されています.

科学分野:

腫瘍学
血液学
薬理学について

背景:

化学療法による血小板減少 (CIT) は,胃腸がんの治療における重大な合併症である.
オキシリプラチンを含む治療法は標準ですが,高いCIT率と関連しており,有害な結果をもたらします.
CITの病理生理学を理解することは,消化器官の悪性腫瘍を効果的に管理するために不可欠です.

研究の目的:

胃腸がんにおける化学療法による血栓縮小の総合的な見直しを行う.
CITのメカニズム,臨床的影響,管理戦略を調査する.
特定の化学療法剤と新興治療法の役割を強調する.

主な方法:

胃腸がんにおけるCITの病理生理学,臨床的影響,および管理に関する文献レビュー.
様々な化学療法療法と関連した発生率の分析
現在の治療戦略と新たな治療戦略の概要

主要な成果:

CITは固体腫瘍患者の20~25%に影響し,特定の化学療法 (例えばゲムシタビン,カルボプラチン,オクサリプラチン) の割合は高い.
FOLFOXIRIやS-1プラスオクサリプラチンのような治療法は,胃腸がんにおいてより高いCIT発生率を示しています.
治療には,投与量調整,血小板輸血,およびトロンボポエチン受容体アゴニスト (TPO- RAs) が含まれる.

結論:

CITは胃腸がんの化学療法における一般的で深刻な合併症であり,治療の実施と患者の安全に影響を及ぼします.
オキシリプラチンはCITに関連した重要な薬であり,慎重に管理する必要があります.
TPO-RAと新薬は,CITを緩和し,化学療法用量の強度を維持する見込みを示しています.

キーワード:

フルフィリノックスフルフォックス化学療法による血栓縮小エルトロンボパグ胃腸がんジェムシタビンオキシリプラチン血小板輸血ロミプラスティムトロンボポエチン受容体アゴニスト

さらに関連する動画

04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.1K

関連する概念動画

01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

259

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

259

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

321

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

321

02:49

Cancer Therapies

7.9K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

7.9K

01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

774

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...

774

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

267

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

267

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...